The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Sara Brucker
Honoraria - Medtronic; MSD
Consulting or Advisory Role - AstraZeneca; Hologic; Lilly; Sanofi Aventis GmbH; Storz
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Ethicon (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Hologic; Lilly; MSD; Storz
 
Hanna Huebner
No Relationships to Disclose
 
Verena Thewes
No Relationships to Disclose
 
Lea Louise Volmer
No Relationships to Disclose
 
Andreas Daniel Hartkopf
Honoraria - Agendia; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly; MSD; Novartis; Onkowissen; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Agendia; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly; MSD; Novartis; Onkowissen; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - Exact Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Exact Sciences; Gilead Sciences; Lilly; MSD Oncology; Novartis; Onkowissen; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Benno Lex
No Relationships to Disclose
 
Bahriye Aktas
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Nina Ditsch
Honoraria - AstraZeneca; Gilead Sciences; MCI Healthcare; MSD Avenir; Novartis; Pfizer; Roche; Seagen; TEVA
 
Lothar Haeberle
No Relationships to Disclose
 
Katharina Seitz
No Relationships to Disclose
 
Daniel Anetsberger
No Relationships to Disclose
 
Naiba Nabieva
Employment - Novartis
 
Christian Roos
Employment - Novartis
 
Erik Belleville
Honoraria - AstraZeneca; B. Braun; BMS Brazil; Gilead Sciences; Hexal; Ipsen; Lilly O.; MSD; Novartis; Onkowissen; Pfizer; Roche; Sandoz; Sanofi; Sun Pharma
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Aurikamed; Bayer; Celgene; ClinSol; Connectmedica; Gilead Sciences; GlaxoSmithKline; I-MED; Lilly; MCI Deutschland; Metaplan; MSD; NanoString Technologies; Novartis; Onkowissen; Pfizer; Pierre Fabre; Promedicis; Roche; Seagen; Streamedup!; Tesaro; Teva; Thieme
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Pfizer; Roche
 
Volkmar Mueller
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Eisai; Gilead Sciences; GlaxoSmithKline; high5 Oncology; Medac; Medscape; MSD; Novartis; Onkowissen; Pfizer; Roche; Seagen; Teva
Consulting or Advisory Role - Amgen Foundation; ClinSol; Daiichi Sankyo Pharmaceutical; Eisai; Gilead Sciences; Hexal; Lilly O.; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo Pharmaceutical; Pfizer; Roche
 
Wolfgang Janni
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly O.; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Lilly O.; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; Seagen
Research Funding - Amgen; Janssen Diagnostics; Lilly O.; Menarini Silicon Biosystems; Novartis; Pfizer; Roche
 
Tanja N. Fehm
Honoraria - Amgen; Celgene; Daiichi Sankyo Pharmaceutical; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Daiichi Sankyo Nordics; Novartis; Pfizer; Roche